"To expand on the clinically significant response data observed across a broad population of acute myeloid leukemia (AML) patients during the dose escalation and exploration phase of our trial, we rapidly transitioned to our APTIVATE Phase 1/2 expansion trial with tuspetinib. APTIVATE already is running smoothly with several AML patients being treated in the monotherapy arm, and patient enrollment now is underway in the doublet combination treatment arm with tuspetinib and venetoclax (TUS/VEN). And we are eager to bring additional data to you throughout the year," said William Rice, chairman, president and CEO. "We anticipate enrolling up to 100 patients in the APTIVATE study, from which we expect to demonstrate single agent activity that can guide multiple paths for potential accelerated approval in patients with adverse mutations, and to demonstrate activity in doublet and then triplet combination therapies, which we believe represent the future directions of AML treatment. Tuspetinib’s single agent activity targets more AML populations than SYK inhibitors, IRAK4 inhibitors, or menin inhibitors, and, its distinctly favorable safety profile also lends itself to an ideal combination treatment to potentially treat larger AML patient populations in earlier lines of therapy."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on APTO:
- Aptose Reports Results for the Fourth Quarter and Full Year 2022
- Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
- Aptose Biosciences says immaterial financial exposure to Silicon Valley Bank
- Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
- Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference